Prof. Dr. med. Sebastian Kobold
Principal Investigator
I studied medicine in Bordeaux, Homburg and Zurich and performed my doctoral thesis in the laboratory of C. Renner and A. Knuth in Zurich. After graduating from medical school, I started my residency in Hamburg and worked with D. Atanackovic in the field of tumor immunology. After a stay at Dana-Farber Cancer Institute, Boston, I established my own research group at the University hospital of the LMU. I am a board certified immunologist and clinical pharmacologist. Since 2019, I serve as Professor of Medicine and Experimental Immunooncology and as deputy director of the Division of Clinical Pharmacology at the University Hospital of the LMU. My research is focused on developing and testing novel strategies to treat cancer using the immune system. My goal is to bring these innovations to the clinics to the benefit of patients affected from cancer. Most of my free time is dedicated to my family and in what might be left of it, I run.
Curriculum vitae
- Since 2019 Professor of Medicine and Experimental Immunooncology (W2-level), Deputy Director, Faculty of Medicine, Division of Clinical Pharmacology, University Hospital of Ludwig-Maximilian University Munich (KUM), Germany.
- Since 2016 Attending Physician, Division of Clinical Pharmacology, KUM, Germany.
- 2014 Habilitation in Experimental Internal Medicine, Faculty of Medicine, Ludwig-Maximilians-University Munich (LMU), Germany, Topic: antibody therapy. Supervisors: S. Endres, W. Zimmermann and R. Henschler.
- 2014 Board Certification as Clinical Pharmacologist and Immunologist. Bavarian Chamber of Physicians and German Society of Immunology (DGFI).
- 2010 Dr. med. (medical doctorate), Faculty of Medicine, Saarland University, Homburg, Germany; Supervisors: Renner C., Knuth, Title: “Serologische Identifikation von Pankreaskarzinom-spezifischen Antigenen".
- 2007 Graduation from Medical School and German Licence to practice Medicine. Faculty of Medicine, Saarland University, Homburg, Germany, with electives in Bordeaux, France, Zürich, Switzerland and Homburg, Germany.
- 2023 Georges-Köhler Award, German Society for Immunotherapy, Germany.
- 2022 Monika-Kutzner Award for Cancer Research, Berlin-Brandenburg Academy of Sciences, Germany.
- 2021 Lisec-Artz Award for Cancer Research, Medicine Faculty – University of Bonn, Germany.
- 2020 Clinical Science Award, German Society for Immunotherapy, Germany.
- 2019 M4-preseed Award by the Bavarian Ministry of Economical Affairs.
- 2019 Johann-Georg-Zimmermann Award for Cancer Research, University of Hannover, Germany.
- 2017 European Research Council (ERC) Starting Grant, Brussels, Belgium.
- 2017 Hugo-Wilhelm- von Ziemsen Award for medical research, Department of Internal Medicine IV, University Hospital of Ludwig-Maximilian University Munich (KUM), Germany.
- 2016 Vincenz-Czerny Award for Cancer Research, German Society of Hematology and Oncology, Germany.
- 2016 BMS-MRA Young Investigator Award, awarded by the Melanoma Research Alliance, Washington D.C., USA.
- 2016 Career Advancement Award 2016 of the Jung-Foundation for Science and Research, Hamburg, Germany.
- 2016 Young investigator Award, Melanoma Research Alliance, Washington D.C., USA.
- 2023 Section Editor at the Journal for the Immunotherapy of Cancer (JIF 12.5), official journal of the Society for the Immunotherapy of Cancer (SITC).
- 2022 Editorial Board Member, ESMO IOTECH.
- 2020 Associate Editor for the Section Cancer Immunity and Immunotherapy. Frontiers in Immunology (JIF 5) and Frontiers in Oncology (JIF 4.8).
- Bispecific antibody molecules with antigen-transfected T cells and their use in medicine. Kobold S, Bourquin C, Castoldi R, Sustmann C, Niederfellner G, Klein C and Endres S. PCT/EP2013/051351.
- PD1-CD28 fusions proteins and their use in medicine. Kobold S and Endres S. PCT/EP2016/064195.
- CXCR6 transduced T cells for targeted tumor therapy. Kobold S, Grassmann S, Rapp M and Endres S. EP15190179.0, submitted on October 16th 2015.
- Improving adoptive cellular therapy. Kobold S, Geiger M, Sustmann C, Niederfellner G, Klein C and Endres S. EP16177203, submitted on June 30th 2016.
- CCR8 transduced T cells for targeted tumor therapy. Kobold S, Cadilha BL and Endres S. EP19161708.3, submitted on march 3rd 2019.
- CSF1R-targeted immunotherapies. Kobold S, Lesch S, Gottschlich A, Endres S. EP21191376, submitted on August 13th 2021.